Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia

PHASE3CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

Not specified

Conditions
Herpes ZosterNeuralgiaPainPeripheral Nervous System Diseases
Interventions
DRUG

Capsaicin Dermal Patch

Trial Locations (19)

27103

NeurogesX Investigational Site, Winston-Salem

30060

NeurogesX Investigational Site, Marietta

30328

NeurogesX Investigational Site, Atlanta

33437

NeurogesX Investigational Site, Boynton Beach

33614

NeurogesX Investigational Site, Tampa

33907

NeurogesX Investigational Site, Fort Myers

34102

NeurogesX Investigational Site, Naples

34205

NeurogesX Investigational Site, Bradenton

63108

NeurogesX Investigational Site, St Louis

63141

NeurogesX Investigational Site, St Louis

75235

NeurogesX Investigational Site, Dallas

78229

NeurogesX Investigational Site, San Antonio

84107

NeurogesX Investigational Site, Salt Lake City

85032

NeurogesX Investigational Site, Phoenix

85210

NeurogesX Investigational Site, Mesa

85381

NeurogesX Investigational Site, Peoria

91010

NeurogesX Investigational Site, Duarte

95403

NeurogesX Investigational Site, Santa Rosa

02135

NeurogesX Investigational Site, Brighton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

NeurogesX

INDUSTRY

NCT00068081 - Controlled Study of NGX-4010 for the Treatment of Postherpetic Neuralgia | Biotech Hunter | Biotech Hunter